Cephalon, Inc. announced today that the U.S. Patent and Trademark Office has issued a pharmaceutical formulation patent for Amrix(R) (Cyclobenzaprine Hydrochloride Extended-Release Capsules). U.S. Patent No. 7,387,793 was issued to Eurand Inc., the developer of Amrix, and expires on February 26, 2025. Last year, Cephalon acquired an exclusive license from Eurand to market AMRIX in North America. The issued claims cover Eurand's proprietary Diffucaps(R) technology used to formulate AMRIX as an extended-release capsule containing the muscle relaxant cyclobenzaprine. The AMRIX formulation allows, for the first time, a full day of cyclobenzaprine in a single dose medication for the treatment of acute painful musculoskeletal conditions.
The details can be read here.
No comments:
Post a Comment